Merck & Co. Signs Major Drug Delivery Deal with SurModics
Business Review Editor
Abstract
Merck & Co. has committed up to US$308 M to license and research collaboration agreement with SurModics. The alliance with SurModics aims to pursue the joint development and commercialization of SurModics’ I-vation™ sustained drug delivery system in combination with triamcinolone acetonide.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.